The global oncology clinical trials market size is expected to reach USD 16.6 billion by 2027, expanding at a CAGR of 5.4%, according to a new report by Grand View Research, Inc. Increasing number of cancer cases and deaths due to the disease and rising demand for precision and personalized medicine to cure the disease is boosting the market growth.
The burden of cancer continues to increase due to the aging population and increasing adoption of behavioral patterns, mostly the sedentary lifestyle, dietary changes with an inclination towards junk foods, as well as smoking. In the last few years, oncology research has seen an increased focus on targeted therapies and personalized medicine. There has been a steady rise in the novel therapeutic approaches and oncology clinical trials owing to the continuous advances and shift in treatment modalities towards targeted anti-cancer drugs.
Get PDF sample copy with TOC of Global Oncology Clinical Trials Market Research Report @ https://www.grandviewresearch.com/industry-analysis/oncology-clinical-trials-market/request/rs1
Clinical research has become an important element to address the global burden of cancer in improving the patient’s life. As per the 2019 report of IQVIA Institute for Human Data Science, out of the top 33 big pharmaceutical firms, 28 firms are developing anti-cancer molecules. The drug pipeline depicts no signs of slackening down. There are more than 600 firms that are having one or more drugs in the late-stage drug development for cancer.
Besides, the innovations in this field are also driving the market. Better insight into the etiology and classification of different types of tumors has led to a shift in the strategies of oncology treatment. Innovation is a prominent trend in oncology drug development. This is seen in the rise in the number of first-in-class drugs entering the market since 2015.
Oncology Clinical Trials Market Report Highlights
- The phase II segment dominated the market with a share of 45.8% in 2019. This is attributed to the increasing number of applications for Phase II
- The interventional design segment accounted for the largest share of 87.9% in 2019 due to the increasing number of drugs in interventional studies
- North America held 55.0% of the market share in 2019. Favorable government initiatives and the presence of a large number of players in the U.S. offering advanced services are responsible for market growth
- In Asia Pacific, the market is expected to witness the fastest CAGR of 7.4% over the forecast period, owing to the increasing patient pool and cost-efficient services.
For Purchase Options or any Inquire about Oncology Clinical Trials Market please visit @: https://www.grandviewresearch.com/inquiry/450919/ibb
Oncology Clinical Trials Market Segmentation
Grand View Research has segmented the global oncology clinical trials market based on phase, study design, caner type, and region:
Oncology Clinical Trials Phase Outlook (Revenue, USD Million, 2016 – 2027)
- Phase I
- Phase II
- Phase III
- Phase IV
Oncology Clinical Trials Study Design Outlook (Revenue, USD Million, 2016 – 2027)
- Interventional
- Observational
- Expanded Access
Oncology Clinical Trials Cancer Type Outlook (Revenue, USD Million, 2016 – 2027)
- Lung cancer
- Thyroid cancer
- Leukemia
- Liver cancer
- Skin cancer
- Lymphoma
- Pancreatic cancer
- Prostate cancer
- Colon & rectal cancer
- Urinary system cancer
- Other cancer
Oncology Clinical Trials Regional Outlook (Revenue, USD Million, 2016 – 2027)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- India
- Japan
- China
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
List of Key Players of Oncology Clinical Trials Market
- IQVIA
- PAREXEL International Corporation
- Pharmaceutical Product Development, LLC
- Charles River Laboratory
- ICON Plc
- PRA Health Sciences
- Syneos Health
- Medpace
- Novotech
- Pivotal
Browse Related Reports :
Oncology Based In-vivo CRO Market Analysis By Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2018 – 2025.
https://www.grandviewresearch.com/industry-analysis/oncology-based-in-vivo-cro-market
Novel Drug Delivery Systems in Cancer Therapy Market Analysis By Product (Nanoparticles and Embolization Particles), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2018 – 2025.
https://www.grandviewresearch.com/industry-analysis/novel-drug-delivery-systems-in-cancer-therapy
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.A based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/oncology-clinical-trials-market